Literature DB >> 27708295

Snakebites: costing recombinant antivenoms.

Andreas H Laustsen1.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27708295     DOI： 10.1038/538041e

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  3 in total

Review 1.  Recombinant antibody mixtures: production strategies and cost considerations.

Authors:  Søren K Rasmussen; Henrik Næsted; Christian Müller; Anne B Tolstrup; Torben P Frandsen
Journal:  Arch Biochem Biophys       Date:  2012-07-20       Impact factor: 4.013

2.  Economics of recombinant antibody production processes at various scales: Industry-standard compared to continuous precipitation.

Authors:  Nikolaus Hammerschmidt; Anne Tscheliessnig; Ralf Sommer; Bernhard Helk; Alois Jungbauer
Journal:  Biotechnol J       Date:  2014-04-04       Impact factor: 4.677

3.  Vipers, mambas and taipans: the escalating health crisis over snakebites.

Authors:  Carrie Arnold
Journal:  Nature       Date:  2016-09-01       Impact factor: 49.962
  3 in total
  12 in total

1.  In vitro discovery of a human monoclonal antibody that neutralizes lethality of cobra snake venom.

Authors:  Line Ledsgaard; Andreas H Laustsen; Urska Pus; Jack Wade; Pedro Villar; Kim Boddum; Peter Slavny; Edward W Masters; Ana S Arias; Saioa Oscoz; Daniel T Griffiths; Alice M Luther; Majken Lindholm; Rachael A Leah; Marie Sofie Møller; Hanif Ali; John McCafferty; Bruno Lomonte; José M Gutiérrez; Aneesh Karatt-Vellatt
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 6.440

2.  Recombinant snakebite antivenoms: A cost-competitive solution to a neglected tropical disease?

Authors:  Andreas H Laustsen; Kristoffer H Johansen; Mikael Engmark; Mikael R Andersen
Journal:  PLoS Negl Trop Dis       Date:  2017-02-03

Review 3.  Innovative Immunization Strategies for Antivenom Development.

Authors:  Erick Bermúdez-Méndez; Albert Fuglsang-Madsen; Sofie Føns; Bruno Lomonte; José María Gutiérrez; Andreas Hougaard Laustsen
Journal:  Toxins (Basel)       Date:  2018-11-02       Impact factor: 4.546

4.  Integrating Engineering, Manufacturing, and Regulatory Considerations in the Development of Novel Antivenoms.

Authors:  Andreas Hougaard Laustsen; Netty Dorrestijn
Journal:  Toxins (Basel)       Date:  2018-07-31       Impact factor: 4.546

5.  Biosynthetic Oligoclonal Antivenom (BOA) for Snakebite and Next-Generation Treatments for Snakebite Victims.

Authors:  R Manjunatha Kini; Sachdev S Sidhu; Andreas Hougaard Laustsen
Journal:  Toxins (Basel)       Date:  2018-12-13       Impact factor: 4.546

6.  A synthetic biology approach for consistent production of plant-made recombinant polyclonal antibodies against snake venom toxins.

Authors:  Jose Manuel Julve Parreño; Estefanía Huet; Asun Fernández-Del-Carmen; Alvaro Segura; Micol Venturi; Antoni Gandía; Wei-Song Pan; Irene Albaladejo; Javier Forment; Davinia Pla; Andrés Wigdorovitz; Juan J Calvete; Carlos Gutiérrez; José María Gutiérrez; Antonio Granell; Diego Orzáez
Journal:  Plant Biotechnol J       Date:  2017-09-22       Impact factor: 9.803

7.  Snakebite: An Exploratory Cost-Effectiveness Analysis of Adjunct Treatment Strategies.

Authors:  Benjamin J Herzel; Stephen P Samuel; Tommaso C Bulfone; C Soundara Raj; Matthew Lewin; James G Kahn
Journal:  Am J Trop Med Hyg       Date:  2018-05-31       Impact factor: 2.345

8.  Delayed Oral LY333013 Rescues Mice from Highly Neurotoxic, Lethal Doses of Papuan Taipan (Oxyuranus scutellatus) Venom.

Authors:  Matthew R Lewin; José María Gutiérrez; Stephen P Samuel; María Herrera; Wendy Bryan-Quirós; Bruno Lomonte; Philip E Bickler; Tommaso C Bulfone; David J Williams
Journal:  Toxins (Basel)       Date:  2018-09-20       Impact factor: 4.546

Review 9.  Recent Advances in Next Generation Snakebite Antivenoms.

Authors:  Cecilie Knudsen; Andreas H Laustsen
Journal:  Trop Med Infect Dis       Date:  2018-04-15

Review 10.  Basics of Antibody Phage Display Technology.

Authors:  Line Ledsgaard; Mogens Kilstrup; Aneesh Karatt-Vellatt; John McCafferty; Andreas H Laustsen
Journal:  Toxins (Basel)       Date:  2018-06-09       Impact factor: 4.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.